Guangzhou Concord Cancer Center, a subsidiary of Concord Healthcare Group Co., Ltd., has achieved a significant milestone by completing China's first proton therapy treatment for choroidal malignant melanoma. This advancement offers a novel eye-preserving treatment option for this common intraocular malignancy, which traditionally required enucleation, leading to permanent blindness. Utilizing advanced pencil beam scanning proton therapy and real-time image guidance, the center ensures high-dose, precise irradiation of the target area while protecting critical neighboring structures. This development fills a crucial gap in the field and provides new hope for patients with this condition.